User:Mr. Ibrahem/Caplacizumab

Caplacizumab, sold under the brand name Cablivi, is a medication used to treat thrombotic thrombocytopenic purpura (TTP). It is used with plasma exchange and immunosuppressive therapy. It is given by injection into a vein or under the skin.

Common side effects include nosebleeding, headaches, and bleeding gums. Use in pregnancy may increase the risk of bleeding in the baby. It is a small antibody that attaches to and inactivates von Willebrand factor.

Caplacizumab was approved for medical use in Europe in 2018 and the United States in 2019. In the United Kingdom a month of treatment costs about £125,000 as of 2021. This amount in the United States costs about 230,000 USD.